| 前收盘价格 | 120.87 |
| 收盘价格 | 121.10 |
| 成交量 | 329,571 |
| 平均成交量 (3个月) | 716,625 |
| 市值 | 7,109,886,976 |
| 预期市盈率 (P/E Forward) | 2.00 |
| 价格/销量 (P/S) | 11.12 |
| 股市价格/股市净资产 (P/B) | 9.32 |
| 52周波幅 | |
| 利润日期 | 29 Apr 2026 |
| 营业毛利率 | -30.57% |
| 营业利益率 (TTM) | -19.39% |
| 稀释每股收益 (EPS TTM) | -2.27 |
| 季度收入增长率 (YOY) | 24.60% |
| 总债务/股东权益 (D/E MRQ) | 14.09% |
| 流动比率 (MRQ) | 6.49 |
| 营业现金流 (OCF TTM) | -45.97 M |
| 杠杆自由现金流 (LFCF TTM) | -17.66 M |
| 资产报酬率 (ROA TTM) | -6.68% |
| 股东权益报酬率 (ROE TTM) | -20.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | Glaukos Corporation | 看涨 | 看跌 |
AIStockmoo 评分
-1.1
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -3.5 |
| 平均 | -1.13 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.33% |
| 机构持股比例 | 101.71% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HOFFMEISTER DAVID F | - | - | 0 | 0 |
| 累积净数量 | 0 | |||
| 累积净值 ($) | 0 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| HOFFMEISTER DAVID F | 董事 | 26 May 2026 | 执行期权 | 15,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合